Aevi Genomic Medicine, LLC Sustainability Profile
Aevi Genomic Medicine, LLC, a pioneering entity in the field of genomic medicine, is headquartered in the United States. Founded in 2013, the company has established itself as a leader in developing innovative therapies for rare genetic disorders, particularly focusing on paediatric populations. With a commitment to advancing precision medicine, Aevi Genomic Medicine offers unique solutions that leverage genomic insights to tailor treatments for individual patients. Their proprietary platform integrates advanced genomic technologies, setting them apart in the competitive landscape of biotechnology. Recognised for their significant contributions to the industry, Aevi has achieved notable milestones, including successful clinical trials that underscore their position as a key player in the genomic medicine sector. As they continue to expand their operational reach, Aevi remains dedicated to transforming the lives of patients through cutting-edge genomic therapies.
DitchCarbon Score
How does Aevi Genomic Medicine, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aevi Genomic Medicine, LLC's score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aevi Genomic Medicine, LLC's reported carbon emissions
Aevi Genomic Medicine, LLC, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a merged entity, Aevi Genomic Medicine's climate commitments and emissions data may be influenced by its corporate family relationships; however, no specific cascading data from parent organisations has been provided. This lack of information suggests that the company may still be in the early stages of developing its climate strategy or reporting framework. In the context of the industry, it is essential for companies like Aevi Genomic Medicine to establish clear emissions reduction targets and commitments to align with global climate goals. Without specific data or initiatives, the company faces challenges in demonstrating its commitment to sustainability and climate action.
How Carbon Intensive is Aevi Genomic Medicine, LLC's Industry?
How Carbon Intensive is Aevi Genomic Medicine, LLC's Location?
Aevi Genomic Medicine, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aevi Genomic Medicine, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
